Dr. Susan Desmond-Hellman, Genentech president of product development

Susan Desmond-Hellmann, who gets much of the credit for Genentech's string of development successes, has more than a million shares and options. Now Desmond-Hellman and others could become so rich from Roche's $95 a share offer, some analysts fret they're likely to up and quit. And those are exactly the people that Roche most needs to stay at work, creating new therapies.

Related Articles:
Development chief outlines strategy at Genentech
Roche to shed jobs in merger with "California cowboys"
What's next for Genentech employees?
Genentech aims to keep staff with $371M